ReviewHematology/oncology clinics of North America2015
Molecular biology of bladder cancer.
Review in Hematology/oncology clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer.Nature communications · 2026Article
- Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.Scientific reports · 2023Article
- Novel genomic alteration in superficial esophageal squamous cell neoplasms in non-smoker non-drinker females.Scientific reports · 2021Article
- LINC00460 Enhances Bladder Carcinoma Cell Proliferation and Migration by Modulating miR-612/FOXK1 Axis.Pharmacology · 2021Article
- Role of tyrosine kinases in bladder cancer progression: an overview.Cell communication and signaling : CCS · 2020Review
- Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles.Cancers · 2020Review
- Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity.BMC urology · 2020Article
- Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2020Review
- Review
- Special Issue on Molecular Research Efforts in Urothelial Carcinoma: Summary of Included Topics.International journal of molecular sciences · 2019Article
- Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.International journal of molecular sciences · 2019Article
- Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.American journal of translational research · 2019Article
- Long noncoding RNA LINC01296 promotes cancer-cell proliferation and metastasis in urothelial carcinoma of the bladder.OncoTargets and therapy · 2019Article
- RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.Oncology letters · 2018Article
- Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes.Technology and health care : official journal of the European Society for Engineering and Medicine · 2018Article
- Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma.OncoTargets and therapy · 2017Article
- Altered primary chromatin structures and their implications in cancer development.Cellular oncology (Dordrecht, Netherlands) · 2016Review
- Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.Oncotarget · 2016Article
- H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Classic as well as more recent large-scale genomic analyses have uncovered multiple genes and pathways important for bladder cancer development. Genes involved in cell-cycle control, chromatin regulation, and receptor tyrosine and PI3 kinase-mammalian target of rapamycin signaling pathways are commonly mutated in muscle-invasive bladder cancer. Expression-based analyses have identified distinct types of bladder cancer that are similar to subsets of breast cancer, and have prognostic and therapeutic significance. These observations are leading to novel therapeutic approaches in bladder cancer, providing optimism for therapeutic progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.